Search
Rimegepant
go.drugbank.com/drugs/DB12457ApprovedInvestigational[L41640] While several parenteral antagonists of CGRP and its receptor have been approved for migraine therapy (e.g. … safer for use in patients with contraindications to standard therapy.
Categories: Calcitonin Gene-Related Peptide Receptor AntagonistsAlginic acid
go.drugbank.com/drugs/DB13518ApprovedInvestigationalWithdrawnAlginate-based raft-forming formulations in the management of heartburn and gastric acid reflux have been used worldwide for over 30 years [A32961]. … Available in different types of salt, alginic acid has been used in a variety of uses in food, cosmetics and pharmaceu-tical products for over 100 years [A32961].
Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)Turoctocog alfa pegol
go.drugbank.com/drugs/DB14738ApprovedInvestigationalthat is less frequent than that for turoctocog alfa. … As such, turoctocog alfa pegol is a valuable expansion to the drug therapies available for treating hemophilia A as it ultimately provides a less burdensome and more convenient dosing regimen for patients
Dimethyl fumarate
go.drugbank.com/drugs/DB08908ApprovedInvestigationalDimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis. … [A253917] Prior to its FDA approval, dimethyl fumarate had been used in Germany for treatment of psoriasis.[A253917]
Maralixibat
go.drugbank.com/drugs/DB16226ApprovedInvestigational[L38834] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended maralixibat be granted marketing authorization for the treatment of cholestatic pruritus in patients … [A236823,A239249,L38834] Maralixibat is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome.
Loncastuximab tesirine
go.drugbank.com/drugs/DB16222ApprovedInvestigationalRelapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients who have undergone prior systemic therapies with limited success. … [A234444] On April 23 2021, the Food and Drug Administration granted accelerated approval for the antibody-drug conjugate, loncastuximab tesirine-lpyl, also known as Zynlonta.
Flavin adenine dinucleotide
go.drugbank.com/drugs/DB03147Approved(Lehninger, Principles of Biochemistry, 1982, p972) Flavin adenine dinucleotide is approved for use in Japan under the trade name Adeflavin as an ophthalmic treatment for vitamin B2 deficiency.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesSelinexor
go.drugbank.com/drugs/DB11942ApprovedInvestigationalOther chemotherapies for multiple myeloma include [lenalidomide] and [dexamethasone], [thalidomide], and may include [melphalan] if the patient is not eligible for transplant. … Selinexor, in combination with [bortezomib] and [dexamethasone], is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells.
Lovastatin
go.drugbank.com/drugs/DB00227ApprovedInvestigationalas well as the need for surgical revascularization or angioplasty following a heart attack. … [A181084] Elevated cholesterol levels, and in particular, elevated low-density lipoprotein (LDL) levels, are an important risk factor for the development of CVD.
Categories: Hypolipidemic Agents Indicated for HyperlipidemiaTabelecleucel
go.drugbank.com/drugs/DB17072ApprovedInvestigational[A253292,A253297,L43557] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended tabelecleucel be granted marketing authorization for the treatment of adult and … [L43557] The FDA has granted tabelecleucel Breakthrough Therapy Designation for EBV-associated PTLD following allogeneic HCT.[L43562]